Your session is about to expire
← Back to Search
Duvelisib + BMS-986345 for Lymphoma
Study Summary
This trial is testing a new cancer drug to see if it is safe and effective when used with another cancer drug.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am 18 years old or older.I cannot take preventive treatments for pneumocystis or herpes viruses.I have been diagnosed with a specific type of lymphoma or leukemia.I am 18 years old or older.I haven't had major heart problems or a heart attack in the last 6 months.I am fully active or can carry out light work.I have mantle cell lymphoma and my condition worsened after two treatments.I have a specific type of lymphoma and have tried at least two treatments without success.I haven't had any cancer except for certain skin, bladder, prostate, or cervical cancers in the last 3 years.I had a stem cell transplant from a donor within the last 6 months or from myself within the last 3 months.I do not have any severe ongoing health issues affecting my kidneys, liver, blood, hormones, lungs, brain, or mental health.I have been treated for tuberculosis within the last 2 years.I am not taking, nor plan to take, any strong medications that affect drug metabolism during the study.I have a specific type of lymphoma and have tried at least one or two treatments without success.I haven't taken any cancer drugs or experimental medications recently.I am fully active or have some restrictions but can still care for myself.I have hepatitis B or C.I haven't fully recovered from major surgery complications before starting the study treatment.My side effects from previous treatments are mild or stable.I have not had a stroke or brain bleed in the last 6 months.I haven't had CART cell therapy in the last 90 days or have recovered from its side effects.I am experiencing symptoms of graft-versus-host disease.I am not currently undergoing any form of cancer treatment.I am currently taking high doses of steroids or other drugs that weaken my immune system.I do not have an ongoing infection needing strong medication or had a live vaccine recently.I am HIV positive.I cannot take pills by mouth due to my digestive system issues.My cancer is a type of lymphoid malignancy confirmed by tests.I have a tumor or enlarged lymph node larger than 1.5 cm.My organs and bone marrow are working well.I have heart failure or an irregular heartbeat that is not well-controlled.I have had lymphoma in my brain or spinal cord.I have a specific type of T cell or NK cell cancer.My organs and bone marrow are working well.
- Group 1: Dose Escalation
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many participants are being welcomed into this experiment?
"Affirmative. Clinicaltrials.gov reports that, since its debut on November 18th 2021, this experiment is currently recruiting participants for their research with the aim of registering up to 30 volunteers at a single site."
Are there any other trials that have investigated CC-486's potential applications?
"Currently, 188 studies are running globally on CC-486 with 32 residing in the final phase of clinical trials. Although most investigations originate from Saint Louis, Missouri there are 5790 locations conducting research for this specific medication."
What health issues is CC-486 known to alleviate?
"CC-486 is indicated to treat induction chemotherapy, refractory anemias, and patients who have received two prior therapies."
Has CC-486 been given the stamp of approval by the Food and Drug Administration?
"Due to the nature of a Phase 1 trial where safety and efficacy data is limited, our team at Power assigned CC-486 a rating of 1 on its scale from one to three."
Is this medical experiment actively seeking participants?
"Affirmative. According to information gleaned from clinicaltrials.gov, this research is actively accepting participants. It was first posted on November 18th 2021 and the most recent edit took place on August 15th 2022; the trial seeks 30 people at a single medical centre."
Share this study with friends
Copy Link
Messenger